Sirolimus

Phase 2/3UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 34/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Polycystic Kidney Diseases

Conditions

Polycystic Kidney Diseases

Trial Timeline

Sep 1, 2011 → Aug 1, 2015

NCT ID

NCT01680250

About Sirolimus

Sirolimus is a phase 2/3 stage product being developed by Pfizer for Polycystic Kidney Diseases. The current trial status is unknown. This product is registered under clinical trial identifier NCT01680250. Target conditions include Polycystic Kidney Diseases.

What happened to similar drugs?

3 of 14 similar drugs in Polycystic Kidney Diseases were approved

Approved (3) Terminated (4) Active (7)

✅tredaptive (nicotinic acid/ laropiprant) + placeboMerckApproved

✅Placebo + EverolimusNovartisApproved

✅3 mg DRSP/20 μg EEBayerApproved

🔄Metformin XR + Saxagliptin + Saxagliptin-Metformin XRAstraZenecaPhase 3

🔄Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ERAstraZenecaPhase 3

🔄Lisinopril + Telmisartan + PlaceboMerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04094675	Phase 2	Completed	Sep 16, 2019	Jun 5, 2025	PTEN Gene Mutation
NCT03047980	Phase 2/3	Completed	Jan 1, 2017	Oct 27, 2020	Sturge-Weber Syndrome
NCT01265030	Phase 1/2	Completed	Feb 1, 2014	Dec 22, 2021	Desmoid Tumor
NCT01595841	Phase 2	Completed	Dec 1, 2011	Mar 1, 2022	End Stage Renal Disease
NCT01680250	Phase 2/3	UNKNOWN	Sep 1, 2011	Aug 1, 2015	Polycystic Kidney Diseases
NCT00484094	Pre-clinical	Completed	Jul 1, 2011	Jun 1, 2015	Kidney Transplantation
NCT01236378	Phase 1	Completed	Dec 1, 2010	Apr 1, 2011	Transplant Rejection
NCT00999258	Approved	UNKNOWN	Sep 1, 2009	Jun 1, 2011	Glomerular Filtration Rate
NCT00697112	Pre-clinical	Completed	May 1, 2008	Dec 1, 2012	Renal Transplantation
NCT00555373	Pre-clinical	Completed	Nov 1, 2007	Nov 1, 2012	Renal Transplant
NCT02117596	Pre-clinical	Completed	Nov 1, 2007	Nov 1, 2012	Renal Transplant
NCT00866879	Approved	Completed	Jun 1, 2007	Mar 1, 2019	Renal Transplant Rejection
NCT00282217	Approved	Completed	Aug 1, 2006	—	Kidney Failure
NCT00275522	Approved	Completed	Dec 1, 2005	Dec 1, 2007	Kidney Transplant
NCT00490789	Phase 2	UNKNOWN	Oct 1, 2005	Sep 1, 2009	Tuberous Sclerosis
NCT00137345	Phase 3	Terminated	Jun 1, 2005	Aug 1, 2006	Kidney Transplant
NCT00170053	Phase 1	Completed	Jun 1, 2005	Sep 1, 2008	Kidney Diseases
NCT00195195	Pre-clinical	Completed	Jan 1, 2005	Jun 1, 2008	Transplantation
NCT00189202	Phase 2/3	Completed	Aug 1, 2004	Jul 1, 2008	End Stage Renal Disease
NCT00188955	Approved	Completed	Mar 1, 2004	Oct 1, 2008	Kidney Transplantation

Competing Products

20 competing products in Polycystic Kidney Diseases

See all competitors

Product	Company	Stage	Hype Score
Tildacerfont + Placebo	Spruce Biosciences	Phase 2	17
ABBV-CLS-628 + Placebo	AbbVie	Phase 2	42
Elagolix + Placebo	AbbVie	Phase 2	35
Metformin XR + Saxagliptin + Saxagliptin-Metformin XR	AstraZeneca	Phase 3	40
Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ER	AstraZeneca	Phase 3	40
AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part B	AstraZeneca	Phase 1	36
AZD4901 (oral) + Placebo to match AZD4901	AstraZeneca	Phase 2	35
IVF Antagonist Protocol	Merck	Pre-clinical	22
tredaptive (nicotinic acid/ laropiprant) + placebo	Merck	Approved	43
Lisinopril + Telmisartan + Placebo	Merck	Phase 3	40
Lisinopril + Telmisartan + Placebo	Merck	Phase 3	40
Cetrorelix acetate + Cetrorelix acetate + Recombinant Human Choriogonadotropin (r-hCG) + Recombinant human follicle stimulating hormone (r-hFSH)	Merck	Phase 3	40
Gonal-f® + Long GnRH agonist + GnRH antagonist	Merck	Pre-clinical	26
Placebo + Everolimus	Novartis	Approved	43
LIK066 + Placebo	Novartis	Phase 2	35
Octreotide + Placebo	Novartis	Phase 2/3	38
Everolimus + Calcineurin inhibitors maintenance	Novartis	Phase 3	40
Everolimus + Octreotide LAR	Novartis	Phase 2	35
Atorvastatin + Placebo	Pfizer	Pre-clinical	26
Rapamune	Pfizer	Phase 1/2	32